ArticleInternational journal of nanomedicine2025
Protective Effects of GalNac-Modified Red Blood Cell-Derived Extracellular Vesicles Against Liver Diseases.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Engineered extracellular vesicles for combinatorial cancer therapy and imaging.Acta pharmaceutica Sinica. B · 2026Review
- Interferon Regulatory Factors in Alcohol-Associated Liver Disease: Cell-Type Programs, Danger Signaling, and Therapeutic Opportunities.Current issues in molecular biology · 2026Review
- Extracellular Vesicles: Orchestrators of Intrahepatic and Systemic Crosstalk in Metabolic Dysfunction-Associated Steatotic Liver Disease.Pharmaceutics · 2026Review
- Targeted Delivery of Nucleic Acid Therapeutics: Emerging Carriers and Applications in Common Metabolic and Inflammatory Diseases.International journal of nanomedicine · 2026Review
- High Dihydromyricetin Loaded Biomimetic Nanoemulsion Ameliorated Early Nonalcoholic Fatty Liver Disease by Hepatic Ferroptosis Inhibition.International journal of nanomedicine · 2026Article
- Colon-Targeted astragalus polysaccharide nanoparticles prevent NAFLD-Driven hepatocarcinogenesis via microbiota remodeling and NF-κB Inhibition.Journal of experimental & clinical cancer research : CR · 2025Article
- The Role and Application of MAdCAM-1/α4β7-Induced Lymphocyte Migration in Inflammatory Enterohepatic Diseases.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The high morbidity and mortality of liver diseases warrant the development of more effective therapeutic methods. Extracellular vesicles (EVs) are optimal drug delivery vehicles, albeit with insufficient targeting specificity. The aim of this study was to develop modified red blood cell-derived EVs (RBC-EVs) for targeted drug delivery into hepatocytes, and verify their therapeutic efficacy in animal models of acute liver failure (ALF), non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC). Methods: RBC-EVs were extracted and modified with triantennary N-acetyl galactosamine sequences (GalNac-RBC-EVs), then loaded with drugs or oligonucleotides. The GalNac-RBC-EVs uptake by hepatocytes was monitored both in vitro and in vivo. Models of ALF, NAFLD and HCC were established using C57BL/6J mice. RBC-EVs/GalNac-miR-155-ASO was prepared for the treatment of ALF by anchoring GalNac-miR-155-ASO to RBC-EVs. GalNac-RBC-EVs loaded with PJ34 (GalNac-RBC-EVs/PJ34) were used for treating NAFLD. Finally, GalNac-Rab7-siRNA and PJ34 were co-loaded into RBC-EVs (RBC-EVs/GalNac-Rab7-siRNA/PJ34) as a therapeutic agent for HCC. The therapeutic efficacy, biosafety and stability of the modified RBC-EVs were analyzed as per standard protocols. Results: GalNac-RBC-EVs exhibited higher hepatocyte accumulation via asialoglycoprotein receptor (ASGPR)-mediated uptake both in vivo and in vitro. In ALF, RBC-EVs/GalNac-miR-155-ASO reduced inflammation through suppression of pyroptosis ( Conclusion: Drug-loaded GalNac-RBC-EVs selectively targeted the hepatocytes, and displayed significant therapeutic efficacy in ALF, NAFLD or HCC without any side effects. Altogether, RBC-EVs modified with GalNac are a promising drug carrier for the effective and precise treatment of various liver diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.